B-cell receptors

B-cell re·cep·tors

(sel rĕ-sep'tŏrz)
A complex comprising a membrane-bound immunoglobulin molecule and two associated signal-transducing α- and β-chains.
References in periodicals archive ?
SEATTLE, May 11, 2015 /PRNewswire/ -- Adaptive Biotechnologies, the leader in next generation sequencing (NGS) to profile T- and B-cell receptors, demonstrated in today's issue of Nature Medicine the ability of the immunoSEQ[sup.
The Company leverages advances in next generation sequencing ("NGS") to profile T-Cell and B-Cell Receptors ("TCRs" and "BCRs").
This vaccine concept, using the proven, modern technology of baculovirus VLPs will enable enhanced cross linking of B-cell receptors and favour induction of B-cell responses against common epitopes essential for long-lasting cross recognition and protection.
SEATTLE, May 8, 2015 /PRNewswire/ -- Adaptive Biotechnologies, the leader in next generation sequencing (NGS) to profile T- and B-cell receptors of the adaptive immune system, and its collaborators will present data demonstrating how profiling a patient's T-cell repertoire may lead to diagnostic and therapeutic discovery in immune-mediated diseases at the American Association of Immunologists (AAI) Annual Meeting in New Orleans from May 8-11, 2015.
para]]SEATTLE, May 6, 2015 /PRNewswire/ -- Adaptive Biotechnologies, a leader and pioneer in next generation sequencing (NGS) of T-cell and B-cell receptors in the immune system, announced today the completion of Adaptive's Series F financing round with a $195 million investment to support several strategic growth initiatives.
About Adaptive Biotechnologies Adaptive Biotechnologies Corporation is a platform-based, diagnostic-driven company that leverages NGS to profile T-Cell and B-Cell Receptors.
Adaptive's core immunoSEQ(TM) platform technology utilizes high-throughput, bias-controlled sequencing to profile T- and B-cell receptors, enabling in-depth characterization of the adaptive immune response against cancer.
SEATTLE, March 17, 2015 /PRNewswire/ -- Adaptive Biotechnologies Corporation, the pioneer in leveraging next generation sequencing to profile T-cell and B-cell receptors, today announced that members of the company's management team will present at the following upcoming 2015 conferences:
Adaptive Biotechnologies Corporation is a platform-based, diagnostic-driven company that leverages next generation sequencing to profile T-cell and B-cell receptors.
7, 2015 /PRNewswire/ -- Adaptive Biotechnologies Corporation, a pioneer in leveraging next generation sequencing to profile T-cell and B-cell receptors, today announced the acquisition of Sequenta, Inc.
26, 2014 /PRNewswire/ -- Adaptive Biotechnologies, a pioneer in leveraging Next Generation Sequencing (NGS) to profile T- and B-cell receptors, reported today that the immunoSEQ Assay was able to help identify patients with metastatic melanoma who would be most likely to respond to treatment with pembrolizumab (an anti-PD-1 therapy), according to a study published in this week's issue of Nature.
The Company intends to launch additional research use only immunoSEQ Kits for B-cell receptors and other specific receptor loci, and to expand distribution internationally in 2015.